1

nūhou

ʻAukake

ʻO Melanoma wale nō ka 4% o nā maʻi ʻaʻai āpau akā aia i waena o nā neoplasms cethanus make loa. ʻO Dacarbazine ka lāʻau i koho ʻia no ka mālama ʻana i melanoma ma Brazil ma o ka ʻōnaehana olakino lehulehu ma muli o ke kumu kūʻai haʻahaʻa. Eia nō naʻe, he ʻākela alkylating ia o kahi kikoʻī kikoʻī a elicits i kahi pane therapeutic i 20% wale nō o nā hihia. Kūpono nā lāʻau ʻē aʻe i loaʻa no ka mālama ʻana i ka melanoma, a hoʻomohala mau ʻia nā hunaola tumola i ke kūʻē ʻana i kēia mau lāʻau. Ke koi nei i ka melanoma koi i ka puke hou, nā lāʻau lapaʻau kikoʻī e pono ai i ka luku ʻana i nā pūnaeho kūʻē kūpaʻa lāʻau. ʻO nā lālā ʻo Dibenzoylmethane (1,3-diphenylpropane-1,3-dione) ke hoʻolaha nei i nā agita antitumor. I loko o kēia noi ʻana, ua noiʻi mākou i ka hopena cytotoxic o 1,3-diphenyl-2-benzyl-1,3-propanedione (DPBP) ma nā pūnaewele melanoma B16F10 a me kāna pilina pololei me ka mole DNA e hoʻohana ana i nā tweezers opua. Ua hōʻike ʻo DPBP i nā hopena kūleʻa e kūʻē i nā hunaola tumora a loaʻa kahi papa kuhikuhi selectivity o 41.94. Eia kekahi, hōʻike mākou i ka hiki o DPBP e launa pololei me ka moleola DNA. ʻO ka hiki i ka DPBP ke launa pū me DNA in vitro e ʻae iā mākou e kuhiakau e hiki ke hana i kēlā pilina i loko o vivo a, no laila, he ʻano ʻē aʻe paha ʻo DPBP e mālama i nā mea maʻi me nā melanomas kūpaʻa lāʻau ʻole. Hiki i kēia mau hopena ke alakaʻi i ka hoʻomohala ʻana i nā lāʻau hou a ʻoi aku ka maikaʻi.

Huina kiʻi

3

Kahi o ka pākēneka o ka make cell i loaʻa no ka hui DPBP e kūʻē i nā laina melan-A a me B16F10 i nā ʻano like ʻole. ʻO nā ʻike koho (SI = IC50 melan-A / IC50 B16F10) he 41.94.                    

Paʻi ʻia e Elsevier BV

ʻAukake

ʻO Dibenzoylmethane (DBM) kahi mea liʻiliʻi o ka licorice a me kahi β-diketone analogue o curcumin. ʻO ka hānai ʻana iā 1% DBM i ka papaʻai i nāʻiole Sencar i ka wā o ka hoʻomaka ʻana a me nā wā hoʻomaka ma hope ua kāohi ikaika i ka 7,12-dimethylbenz [a] antracene (DMBA) i hoʻoulu ʻia ka ulu mammary a me nā hanana mammary tumor e 97%. I ke aʻo hou ʻana i loko o ka vivo e elucidate nā hiki i nā hana o ka hana pāpā o DBM, e hānai ana i ka 1% DBM i ka papaʻai AIN-76A i nāʻiole Sencar makua ʻole no 4-5 mau pule i hoʻēmi i ke kaupaona mākū uterine e 43%, ua kāohi i ka nui o ka nui. o nā pūnaewele epithelial mammary gland e 53%, epithelium uterine e 23%, a me stroma uterine e 77%, i ka wā i make ai nāʻiole i ka wā estrus mua o ke kaʻina estrous. Hoʻohui ʻia, hānai ʻana iā 1% DBM i ka papaʻai i nāʻiole Sencar ma 2 mau pule ma mua, a me 1 pule ma hope o ka mālama ʻana o DMBA (intubation o 1 mg DMBA ma kaʻiole hoʻokahi manawa i kēlā me kēia pule no 5 mau pule) ua kāohi i ka hoʻokumu ʻia ʻana o nā mea hoʻohui DMBA a DNA i loko o ka mammary. nā glands e 72% e hoʻohana ana i kahi hoʻāʻo post-32P-lepili. No laila, ʻo ka hānai ʻana i ka ʻai 1% DBM i nā ʻiole Sencar i kāohi i ka hoʻokumu ʻia ʻana o DMBA-DNA addicts i loko o ka momona mammary a hoʻohaʻahaʻa i ka nui o ka nui o ka mammary gland i vivo. Hōʻike paha kēia mau hopena i ka hana pāpā ikaika o ka DBM papaʻai i ka carcinogenesis mammary i nāʻiole.


Ka manawa Post: ʻAuk-12-2020